Home
Axial Therapeutics, Inc.

Axial Therapeutics, Inc. Market Share Analysis for July 2026

Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.

Industry: N/A

Domainaxialbiotherapeutics.com

Year Founded2013

Employees51 - 200

Annual Revenue$10M - $15M

Axial Therapeutics, Inc.

Axial Therapeutics, Inc. (including company regionals)

axialbiotherapeutics.com

See more website traffic and engagement information

Axial Therapeutics, Inc. Revenue up to July 2026 is 10M - 15M

revenue generated by Axial Therapeutics, Inc. top domains

Axial Therapeutics, Inc. top domains revenue over 3 years

Revenue for Axial Therapeutics, Inc. top domains

axialbiotherapeutics.com10M - 15M

See more with Sales Intelligence

Total visits to Axial Therapeutics, Inc.'s top domains

Understand Axial Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Axial Therapeutics, Inc.'s top domains

Analyze Axial Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Axial Therapeutics, Inc.'s top domains

See how Axial Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Axial Therapeutics, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Axial Therapeutics, Inc.

These are the website technologies, by industry, used by Axial Therapeutics, Inc. top domains

Content Management System (3)

WordPress

Mobile (2)

Meta Viewport

Conversion & Analytics (1)

Google Analytics

Email Services (1)

Microsoft Exchange Online

More Technologies

4

See all

News & Signals from Axial Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAxial Biotherapeutics launched AB-2004 on Mar 31st '22.Axial plans to advance its lead product, AB-2004, into a phase 1b/2a clinical trial in adolescents with autism by the end of March.